Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

Introduction: The programmed death-ligand 1 inhibitor atezolizumab improves progression-free survival (PFS) and overall survival (OS) for patients with previously treated advanced NSCLC. Preclinical studies indicate that targeting CD38-positive cells with daratumumab may synergistically enhance atez...

Full description

Bibliographic Details
Main Authors: Rathi N. Pillai, MD, Suresh S. Ramalingam, MD, Meena Thayu, MD, Patricia Lorenzini, RN, Diana A. Alvarez Arias, PhD, Christopher Moy, MS, Natalie Hutnick, PhD, Roland Knoblauch, MD, Huaibao Feng, PhD, Colleen Kane, PhD, Leora Horn, MD, Martin Reck, MD, Santiago Ponce, MD
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:JTO Clinical and Research Reports
Subjects:
Daratumumab
Atezolizumab
Non‒small cell lung cancer
Combination immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301508

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301508

Similar Items